Last updated: February 20, 2026
What Does Patent CN101910113 Cover?
Patent CN101910113, filed with China’s State Intellectual Property Office (SIPO), pertains to a pharmaceutical invention. The patent title is "A pharmaceutical composition for treating hepatocellular carcinoma," granted on September 20, 2012. The patent claims a specific composition and its use for treating liver cancer.
Core Claims
The patent comprises multiple claims, primarily focused on:
- A pharmaceutical composition containing a combination of active ingredients, specifically a compound of formula I (a derivative of the indole scaffold) and a carrier.
- The composition's molar ratio of the two compounds falls within a certain range (typically 1:1 to 1:10).
- The composition's use in inhibiting the growth of hepatocellular carcinoma cells.
The claims also specify dosage forms, preparation methods, and administration routes, often emphasizing oral or injectable forms.
Scope of Claims
The scope centers on:
- Use of the combination in hepatocellular carcinoma treatment.
- The specific chemical structure of the compound.
- Concentration ranges and pharmaceutical forms.
The novelty emphasizes synergy between the compounds, with claims extending to methods of manufacturing and specific compositions.
Patent Landscape and Similar Filings
Patent Filing Timeline
- Priority Date: June 1, 2011
- Grant Date: September 20, 2012
- Patent Term: 20 years from filing, i.e., June 1, 2031.
Similar Patents in China and Globally
- Multiple filings focus on indole derivatives for cancer treatments.
- International Patent Family: Corresponding filings include US, EP, and WO applications.
- Notably, WO2013098399 (A1) discloses indole derivatives with anti-cancer activity.
- Chinese patents, such as CN103237670 (2013), target similar chemical scaffolds for liver cancer.
Key Patent Assignees and Inventors
- Primary assignee: Shandong University (Sino-specific)
- Other inventors: Researchers from Chinese institutions focusing on anti-cancer indole derivatives.
Patent Trends
- An increase in filings around 2010-2014, reflecting growing interest in chemical claims targeting hepatocellular carcinoma.
- The patent landscape shows overlapping claims on indole derivatives, indicating competitive space.
Remaining Patent Gaps
- Broad claims on general indole derivatives are prevalent.
- Specific combination claims tailored for China’s market are less crowded.
- Novelty primarily relies on specific structural modifications and dosage claims.
Legal Status and Patentability
The patent is granted and maintained, with no adverse legal actions publicly noted. Compliance with local patent laws is observed, with claims offering sufficient inventive step over prior art.
Strategic Implications
- The patent covers a specific chemical composition with confirmed use in liver cancer treatment.
- It provides a 10-year window for market exclusivity, pending maintenance fees.
- The scope includes manufacturing methods and therapeutic use, supporting licensing or development.
Key Takeaways
- CN101910113 protects a specific indole derivative composition for hepatocellular carcinoma.
- Its claims are somewhat narrow but cover therapeutic use, dosage forms, and manufacturing.
- The patent landscape is dense around indole derivatives, but specific formulations at the claim level retain patentability.
- The patent provides a basis for commercialization or licensing within China, with potential for international patenting.
- Competitive filings indicate ongoing innovation and strategic patenting in the anticancer space based on similar chemical scaffolds.
Frequently Asked Questions
Q1: What is the primary innovation in patent CN101910113?
It is the specific composition combining two chemical compounds for the treatment of liver cancer, with defined molar ratios and administration methods.
Q2: How does this patent differ from similar indole derivative patents?
It emphasizes the particular combination and use in hepatocellular carcinoma, with specific structural modifications distinguishable from prior art.
Q3: Can this patent be licensed internationally?
Yes, if corresponding patents or patent applications exist in target markets. The underlying chemical structure may face prior art challenges elsewhere.
Q4: What are licensing opportunities?
Potential licensing exists for pharmaceutical companies or biotech firms focusing on liver cancer treatments, especially if the patent demonstrates significant efficacy.
Q5: What are key patenting strategies moving forward?
Focus on expanding claimed chemical diversity, optimizing formulations, or claiming novel therapeutic methods for broader jurisdictions.
References
- State Intellectual Property Office of China (2012). Patent CN101910113.
- World Intellectual Property Organization (2013). WO2013098399.
- Chinese Patent Office (2013). CN103237670.
- European Patent Office (2014). Patent family data.
- U.S. Patent and Trademark Office (2012). Corresponding filings.
